New Orleans - Ochsner Health physicians Dr. Richard Zweifler and Dr. Joseph Tarsia are co-authors on a post hoc analysis carried out in the ARCADIA randomized clinical trial, comparing the ...
Please provide your email address to receive an email when new articles are posted on . Apixaban did not reduce recurrent stroke risk in patients with atrial cardiopathy without AF. The ARCADIA trial ...
Similar risks seen for apixaban and dabigatran vs aspirin, while rates were higher for rivaroxaban. HealthDay News — Rates of major bleeding and intracranial hemorrhage are similar for apixaban and ...
STOCKHOLM, Aug 31 (Reuters) - An experimental drug from Bristol-Myers Squibb and Pfizer reduces the risk of stroke by more than half compared with aspirin, with no significant rise in major bleeding, ...
The trial enrolled patients with cryptogenic stroke and evidence suggestive of atrial cardiopathy, but no evidence of atrial fibrillation, who were randomized to apixaban, 5 mg or 2.5 mg twice daily, ...
Please provide your email address to receive an email when new articles are posted on . Apixaban and aspirin offered comparable protection against major ischemic or hemorrhagic event for those with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback